This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
269
0.015%, three day treatment
Vehicle gel, three day treatment
Dermatology Research Associates
Los Angeles, California, United States
Patients With Complete Clearance of Actinic Keratosis (AK) Lesions.
Complete clearance rate of actinic keratosis (AK) lesions, defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area.
Time frame: 57 days
Patients With Partial Clearance of Actinic Keratosis (AK)
Patients with partial clearance defined as ≥ 75% reduction in the number of actinic keratosis (AK) lesions identified at baseline in the treatment area
Time frame: baseline and 57 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dermatology Specialists Inc
Oceanside, California, United States
Skin Surgery Medical Group Inc.
San Diego, California, United States
Conant Medical Group
San Francisco, California, United States
University of Miami, Skin Research Camp
Miami, Florida, United States
Atlanta Dermatology, Vein & Research Center, LLC
Alpharetta, Georgia, United States
Medaphase Inc
Newnan, Georgia, United States
Glazer Dermatology
Buffalo Grove, Illinois, United States
Dawes Fretein Clinical Research Group, LLC
Indianapolis, Indiana, United States
Pedia Research LLC
Owensboro, Kentucky, United States
...and 11 more locations